Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 3
1986 1
1987 3
1988 2
1989 3
1990 9
1991 8
1992 9
1993 8
1994 9
1995 8
1996 7
1997 14
1998 14
1999 12
2000 19
2001 18
2002 24
2003 52
2004 54
2005 87
2006 88
2007 114
2008 130
2009 153
2010 192
2011 228
2012 236
2013 324
2014 364
2015 388
2016 460
2017 454
2018 545
2019 560
2020 747
2021 440
Text availability
Article attribute
Article type
Publication date

Search Results

5,126 results
Results by year
Filters applied: . Clear all
Page 1
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Zhang Y, et al. Among authors: zhu f. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217362 Free PMC article. Clinical Trial.
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.
Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P. Shah NN, et al. Among authors: zhu f. Nat Med. 2020 Oct;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020647 Clinical Trial.
Structure-based development of human antibody cocktails against SARS-CoV-2.
Wang N, Sun Y, Feng R, Wang Y, Guo Y, Zhang L, Deng YQ, Wang L, Cui Z, Cao L, Zhang YJ, Li W, Zhu FC, Qin CF, Wang X. Wang N, et al. Among authors: zhu fc. Cell Res. 2021 Jan;31(1):101-103. doi: 10.1038/s41422-020-00446-w. Epub 2020 Dec 1. Cell Res. 2021. PMID: 33262454 Free PMC article. No abstract available.
Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L, Pei RJ, Li H, Ma XN, Zhou Y, Zhu FH, He PL, Tang W, Zhang YC, Xiong J, Xiao SQ, Tong XK, Zhang B, Zuo JP. Yang L, et al. Among authors: zhu fh. Acta Pharmacol Sin. 2020 Oct 28:1-7. doi: 10.1038/s41401-020-00556-6. Online ahead of print. Acta Pharmacol Sin. 2020. PMID: 33116249 Free PMC article.
Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China.
Zhang N, Wang C, Zhu F, Mao H, Bai P, Chen LL, Zeng T, Peng MM, Qiu KL, Wang Y, Yu M, Xu S, Zhao J, Li N, Zhou M. Zhang N, et al. Among authors: zhu f. Front Endocrinol (Lausanne). 2020 Sep 24;11:571037. doi: 10.3389/fendo.2020.571037. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33071977 Free PMC article. Clinical Trial.
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.
Liu J, Shu Y, Zhu F, Feng B, Zhang Z, Liu L, Wang G. Liu J, et al. Among authors: zhu f. J Glob Antimicrob Resist. 2021 Mar;24:136-147. doi: 10.1016/j.jgar.2020.08.021. Epub 2020 Sep 2. J Glob Antimicrob Resist. 2021. PMID: 32889142 Free article. Review.
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
So JBY, Kapoor R, Zhu F, Koh C, Zhou L, Zou R, Tang YC, Goo PCK, Rha SY, Chung HC, Yoong J, Yap CT, Rao J, Chia CK, Tsao S, Shabbir A, Lee J, Lam KP, Hartman M, Yong WP, Too HP, Yeoh KG. So JBY, et al. Among authors: zhu f. Gut. 2021 May;70(5):829-837. doi: 10.1136/gutjnl-2020-322065. Epub 2020 Oct 7. Gut. 2021. PMID: 33028667 Free PMC article.
5,126 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page